Form 4: Charles River Labs Director Trades Shares

Director Abraham Ceesay acquired 1,438 shares of common stock in Charles River Laboratories International, Inc. on May 8, 2026.

Summary

• Director Abraham Ceesay acquired 1,438 shares of common stock in Charles River Laboratories International, Inc. on May 8, 2026, at a price of $177.62 per share.
• Following this transaction, Ceesay beneficially owns 2,384 shares of common stock.
• The acquired shares were part of a transaction made pursuant to a written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine insider transaction under a pre-arranged plan, with no new financial information or strategic shifts disclosed.

Positives

• Director acquisition of shares can signal confidence in the company's future prospects.
• The transaction was made under a Rule 10b5-1(c) plan, suggesting a pre-planned and potentially non-insider trading related acquisition.

Future Outlook

The filing does not contain specific forward-looking statements or guidance. However, the acquisition of shares by a director under a Rule 10b5-1(c) plan may imply a positive outlook from management.

Industry Context

StockSavvy.ai notes that director stock purchases, especially under Rule 10b5-1(c) plans, are common in the life sciences and contract research organization (CRO) sector as a way for insiders to manage their personal portfolios while adhering to trading regulations.

Stakeholder Impact

• Shareholders: The purchase by a director may be interpreted as a positive signal of confidence in the company's value.
• Management: The transaction aligns with standard corporate governance practices for executive compensation and stock ownership.

Next Steps

• The unvested restricted stock units will vest on the earlier of May 8, 2027, or the business day prior to the Company's next annual meeting of shareholders.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Stock Acquisition, Charles River Laboratories, Director Transaction, Rule 10b5-1(c)